Terms: = Colorectal cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Clinical Outcome
24 results:
1. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
[TBL] [Abstract] [Full Text] [Related]
2. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic colorectal cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.
Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R
Oncology; 2022; 100(1):1-11. PubMed ID: 34670215
[TBL] [Abstract] [Full Text] [Related]
3. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.
Lim Y; Kim S; Kang JK; Kim HP; Jang H; Han H; Kim H; Kim MJ; Lee KH; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
Sci Rep; 2021 Aug; 11(1):16333. PubMed ID: 34381078
[TBL] [Abstract] [Full Text] [Related]
4. Development of BRAF V600E Mutation in nras Q61L Mutated Rectal cancer.
Cao MN; Chen KT; Li QF; Wang L; Jin GW; Na RT; Ma J; Liu YT; Gao JL
Ann Clin Lab Sci; 2021 Mar; 51(2):262-266. PubMed ID: 33941568
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study.
García-Alfonso P; García-González G; Gallego I; Peligros MI; Ortega L; Torres Pérez-Solero G; Sandoval C; Muñoz Martin A; Blanco Codesido M; Calvo Ferrándiz A; Martin M
Clin Transl Oncol; 2021 Jan; 23(1):122-129. PubMed ID: 32519179
[TBL] [Abstract] [Full Text] [Related]
6. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Holch JW; Held S; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; von Einem JC; Michl M; Heinemann V
Ann Oncol; 2020 Jan; 31(1):72-78. PubMed ID: 31912799
[TBL] [Abstract] [Full Text] [Related]
7.
Papachristos A; Kemos P; Katsila T; Panoilia E; Patrinos GP; Kalofonos H; Sivolapenko GB
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752122
[TBL] [Abstract] [Full Text] [Related]
8. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon cancer.
Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
[TBL] [Abstract] [Full Text] [Related]
9. clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I colorectal cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract] [Full Text] [Related]
10. Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer.
Kim D; Kim SY; Lee JS; Hong YS; Kim JE; Kim KP; Kim J; Jang SJ; Yoon YK; Kim TW
BMC Gastroenterol; 2017 Nov; 17(1):121. PubMed ID: 29169325
[TBL] [Abstract] [Full Text] [Related]
11. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
[TBL] [Abstract] [Full Text] [Related]
12. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract] [Full Text] [Related]
13. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract] [Full Text] [Related]
14. A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Bonin S; Donada M; Bussolati G; Nardon E; Annaratone L; Pichler M; Chiaravalli AM; Capella C; Hoefler G; Stanta G
Tumour Biol; 2016 Jun; 37(6):7295-303. PubMed ID: 26666825
[TBL] [Abstract] [Full Text] [Related]
15. KRAS, nras, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases.
Barresi V; Bonetti LR; Bettelli S
Pathology; 2015 Oct; 47(6):551-6. PubMed ID: 26352110
[TBL] [Abstract] [Full Text] [Related]
16. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract] [Full Text] [Related]
17. Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab.
Giampieri R; Mandolesi A; Abouelkhair KM; Loretelli C; Del Prete M; Faloppi L; Maristella B; Ibrahim EM; Scarpelli M; Cascinu S; Scartozzi M
J Transl Med; 2015 May; 13():140. PubMed ID: 25943333
[TBL] [Abstract] [Full Text] [Related]
18. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic colorectal cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract] [Full Text] [Related]
19. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract] [Full Text] [Related]
20. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: clinical outcome and biomarkers of efficacy.
Pietrantonio F; Perrone F; Biondani P; Maggi C; Lampis A; Bertan C; Venturini F; Tondulli L; Ferrari D; Ricci V; Villa F; Barone G; Bianco N; Ghidini A; Bossi I; Fanetti G; Di Bartolomeo M; de Braud F
Cancer Biol Ther; 2013 Dec; 14(12):1098-103. PubMed ID: 24025413
[TBL] [Abstract] [Full Text] [Related]
[Next]
